In the Boardroom - North America

Filter

Current filters:

North America

Popular Filters

1945 to 1969 of 1984 results

GlaxoSmithKline’s diabetes drug Avandia to be restricted on US market

20-05-2011

As part of a US Food and Drug Administration re-assessment of UK drug giant GlaxoSmithKline’s troubled…

AvandiaDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulation

Sandoz files for generic of Shire’s Vyvanse; FDA warning

20-05-2011

Ireland-headquartered biopharmaceutical company Shire (LSE: SHP) yesterday revealed that its US subsidiary…

GenericsMarkets & MarketingNeurologicalNorth AmericaNovartisPatentsPharmaceuticalRegulationSandozShireVyvanse

FDA advisory panel backs continued use of Abbott’s Trilipix with statins

20-05-2011

The US Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee to review…

Abbott LaboratoriesCardio-vascularNorth AmericaPharmaceuticalRegulationTrilipix

10% of US cancer patients abandoned oral drug therapy, often on cost grounds

20-05-2011

In the USA, 10% of cancer patients failed to fill their initial prescriptions for oral anti-cancer drugs,…

HealthcareNorth AmericaOncologyPharmaceuticalPricing

US cancer drug use and spending to rise sharply by 2013, followed by diabetes and CNS, says Medco

19-05-2011

Expensive new cancer drugs treating increasing numbers of patients could drive cancer drug spending by…

DiabetesMarkets & MarketingNeurologicalNorth AmericaOncologyPharmaceuticalPricing

Public Citizen says US FDA should immediately pull Eisai and Pfizer’s high-dose Aricept from market

19-05-2011

US consumer watchdog Public Citizen has called for higher doses of Aricept (donepezil), marketed by originator…

AriceptEisaiNeurologicalNorth AmericaPfizerPharmaceuticalRegulation

Hepatitis C market rivals Merck & Co and Roche in marketing pact for newly-approved boceprevir

18-05-2011

US drug giant Merck (NYSE: MRK) has entered into agreements with Swiss major Roche (SIX: ROG), through…

Anti-viralsboceprevirMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVictrelis

Pfizer files for US and Japanese approval of crizotinib for NSCLC

18-05-2011

US drug behemoth Pfizer (NYSE: PFE) says that its New Drug Application for crizotinib, an oral first-in-class…

Asia-PacificcrizotinibNorth AmericaOncologyPfizerPharmaceuticalRegulation

Alimera resubmits eye drug Iluvien to US regulator

17-05-2011

USA-based Alimera Sciences (Nasdaq: ALIM) says that it has resubmitted its New Drug Application for Iluvien…

Alimera SciencesIluvienNorth AmericaOphthalmicsPharmaceuticalpSividaRegulation

US FDA clears first hep C drug in a decade, Merck & Co’s Victrelis

16-05-2011

In much awaited, though largely expected news, the US Food and Drug Administration on Friday approved…

Anti-viralsboceprevirMerck & CoNorth AmericaPharmaceuticalRegulationtelaprevirVertexVictrelis

US Medicare likely to run out of funds in 2024; Congressional Affordable Medicines Caucus

16-05-2011

The US Trustees of the Social Security and Medicare trust funds report on the current and projected financial…

GenericsHealthcareNorth AmericaPharmaceuticalPoliticsPricing

Roche files for US and EU approval of vemurafenib for metastatic skin cancer

12-05-2011

US biotech giant Genentech, part of Swiss drug major Roche (SIX: ROG), has submitted a New Drug Application…

Bristol-Myers SquibbDaiichi SankyoEuropeGenentechNorth AmericaOncologyPharmaceuticalPlexxikonRegulationRochevemurafenibYervoy

US concerns about bias in commercially funded continuing medical education

12-05-2011

Commercial funding of continuing medical education (CME) and the potential for bias appear to concern…

North AmericaPharmaceuticalResearch

US FTC warns Sanofi, Watson and Synthon over Ambien patent deal, but won’t take action

11-05-2011

The Federal Trade Commission’s Bureau of Competition has notified Sanofi-Aventis US, a subsidiary…

AmbienGenericsLegalNorth AmericaPatentsPharmaceuticalSanofi-AventisSynthonWatson Pharmaceuticals

US appros of biotech drugs nearly doubled in last decade, says Tufts CSDD

11-05-2011

US regulatory approvals for new biopharmaceuticals nearly doubled in the last decade, compared to the…

BiotechnologyNorth AmericaRegulation

US FDA consults on user fee program for biosimilar and interchangeable biologicals

10-05-2011

The US Food and Drug Administration is requesting input from stakeholders and the public relating to…

BiotechnologyGenericsNorth AmericaPharmaceuticalRegulation

Impax Labs sued again by J&J unit Alza over generic Concerta

09-05-2011

USA-based Impax Laboratories (Nasdaq: IPXL) confirmed on Friday that Alza Corp, a division of health…

ALZA CorpConcertaGenericsImpax LaboratoriesJohnson & JohnsonLegalNeurologicalNorth AmericaPatentsPharmaceuticalTeva Pharmaceutical Industries

Growth in Canadian drug spending slows to lowest rate since 1996

09-05-2011

Although drugs remain an important cost driver in Canada’s health system, growth in spending has…

GenericsHealthcareNorth AmericaPharmaceuticalPricing

Global pharmaceutical market remains in declining growth trend

09-05-2011

The global pharmaceutical market continued to show declining growth through 2010. According to new data…

GlobalMarkets & MarketingNorth AmericaPharmaceutical

Chile remains on USTR Priority Watch list

06-05-2011

The Office of the United States Trade Representative (USTR) released its annual Special 301 Report on…

GenericsLegalNorth AmericaPatentsPharmaceuticalSouth America

US FTC finds 60% rise in pharma pay-for-delay deals; flawed understanding says GPhA

05-05-2011

Pharmaceutical companies in the USA struck an unprecedented number of deals in fiscal year 2010 in which…

GenericsLicensingNorth AmericaPharmaceutical

Merck KGaA US units agree $44.3 million settlement with DoJ; Ranbaxy faces up to $1 billion fine?

05-05-2011

Four US subsidiaries of German drug major Merck KGaA (MRK: DE) - Serono Laboratories, EMD Serono, Merck…

LegalMerck KGaAMerck SeronoNorth AmericaPharmaceuticalRanbaxy LaboratoriesRebif

1945 to 1969 of 1984 results

Company Spotlight

Fibrotech

Fibrotech

Back to top